Mycofenolaatmofetil Auro (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycofenolaatmofetil Auro, is an antimetabolite presented as an oral formulation for oral use. It is employed to prevent acute organ transplant rejection, to treat lupus nephritis, and to manage selected autoimmune disorders in adult patients.

GNH USA supplies Mycofenolaatmofetil Auro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used across several immunological pathways to control abnormal immune activation. - Prevention of acute organ transplant rejection: reduces the risk of graft loss in renal, cardiac and liver transplants. - Lupus nephritis: helps to preserve kidney function by dampening autoimmune inflammation. - Autoimmune disease management: provides disease‑modifying effects in conditions such as systemic lupus erythematosus and other severe autoimmune disorders.

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhoea, or abdominal pain. - Haematologic changes: leukopenia, anaemia, or thrombocytopenia. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Headache or dizziness.

Serious or Rare Side Effects: - Severe infections such as opportunistic or reactivating infections. - Progressive multifocal leukoencephalopathy (PML). - Pregnancy loss or fetal malformations (Category X).

Patients and prescribers should observe several safety measures when using Mycophenolate Mofetil. - Pregnancy avoidance: drug is contraindicated in pregnancy due to teratogenic risk. - Infection monitoring: watch for signs of new or worsening infections and report promptly. - Blood count surveillance: regular complete blood counts to detect leukopenia or anaemia. - Renal function assessment: adjust therapy if significant renal impairment develops. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Mycophenolate Mofetil may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Antacids containing magnesium or aluminium: reduce absorption of mycophenolic acid. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly lower drug exposure.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression; monitor blood counts. - Live vaccines: increased risk of infection; avoid administration during therapy. - Concomitant nephrotoxic agents: heightened risk of renal impairment; assess renal function regularly.